The Risks and Benefits of Indacaterol — The FDA's Review

Badrul A. Chowdhury,Sally Seymour,Theresa Michele,Anthony G. Durmowicz,Dongmei Liu,Curtis J. Rosebraugh

The Risks and Benefits of Indacaterol — The FDA's Review

2011

Badrul A. Chowdhury
Sally Seymour
Theresa Michele
Anthony G. Durmowicz
Dongmei Liu
Curtis J. Rosebraugh

In July, the FDA approved Arcapta Neohaler (indacaterol maleate powder), a long-acting beta-agonist, at a daily dose of 75 μg for chronic obstructive pulmonary disease. Why was this dose selected, after the European Medicines Agency approved 150-μg and 300-μg doses?

Keywords:

Indacaterol
Pharmacology
Medicine
Disease
pulmonary disease
Diabetes mellitus
Alternative medicine
risks and benefits
Surgery
Intensive care medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations